All In Biotech

Drug Trial Radar · NCT05569239

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480μg, After Intramuscular Administration in Healthy Subjects Aged 18-59 Years

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,891 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,891

Actual

Start

Sep 8, 2025

Primary completion

May 18, 2026

Study completion May 18, 2026

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years.

Conditions

  • Influenza

Interventions

  • OVX836 480µgBiological

    One single administration intramuscularly at Day 1.

  • Saline SolutionBiological

    One single administration intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First occurrence of RT-PCR-confirmed influenza Type A symptomatic diseaseTime frame: During the whole study duration, up to maximum 10 months

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Site BE-02

    Antwerp, Belgium

  • Site BE-03

    Antwerp, Belgium

  • Site BE-01

    Ghent, Belgium

  • Site BE-04

    Mechelen, Belgium

  • Site FI-12

    Espoo, Finland

  • Site FI-08

    Helsinki, Finland

  • Site FI-13

    Jarvenpaa, Finland

  • FI-14

    Kokkola, Finland

  • Site FI-11

    Oulu, Finland

  • Site FI-15

    Seinäjoki, Finland

  • Site FI-09

    Tampere, Finland

  • Site FI-10

    Turku, Finland

  • Site FR-05

    Lyon, France

  • Site FR-07

    Paris, France

  • Site FR-06

    Rennes, France

  • Site DE-16

    München, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.